Author: hkaraman

Raising capital in biotech is an ongoing, demanding process. With today’s funding landscape favoring later-stage companies and a select few standout startups, early and mid-stage biopharma firms face increasing challenges attracting investor attention. 

While market factors like interest rates and sector trends are beyond your control, the relationships you build with investors are where you can truly make a difference. Success often hinges on how well you identify, engage, and nurture the right investors for your company’s unique stage and goals. 

Why Investor Targeting is More Art Than Science 

Creating a “target list” of investors isn’t just about naming the biggest or most famous venture capital firms. A strategic, bottom-up approach is critical. Your list should reflect your company’s development phase, fundraising goals, and fit with investors’ current interests and capacity. 

 Consider these factors when building your list: 

• Existing relationships and meeting history: Who do you already know? Have prior conversations laid groundwork? 

• Ownership and investment data: Which investors have stakes in similar companies or therapeutic areas? 

• Investor readiness: Who has available capital (“dry powder”) and appetite for new investments? 

• Current focus areas: Which investors are actively funding your specific biotech sub-sector? 

This targeted approach ensures your outreach is efficient and resonates with those most likely to invest. 

Crafting a Thoughtful Outreach Plan 

Once your target list is assembled, success depends on how you engage. Consider these best practices: 

• Leverage warm introductions: Personal connections increase meeting acceptance rates and build trust early. 

• Time outreach strategically: Align communications around relevant news flow, such as data readouts, partnership announcements, or industry conferences. 

• Prepare tailored messaging: Customize your pitch to reflect the investor’s known interests and priorities. 

Managing Relationships Over Time 

Capital raising is a marathon, not a sprint. Effective relationship management includes: 

• Tracking all interactions: Keep detailed records of meetings, follow-ups, and investor feedback. 

• Establishing a feedback loop: Actively seek and incorporate investor insights to sharpen your pitch and materials. 

• Reassessing and prioritizing: Regularly revisit your target list to tier investors by interest and likelihood of investment. This focus helps you allocate your time where it counts most. 

Why Nurturing Relationships Matters 

Strong investor relationships go beyond a single funding round. They build trust, enable honest dialogue, and often unlock valuable strategic support beyond capital, such as introductions, industry expertise, and operational guidance. 

Well-nurtured relationships increase the chances that investors will stick with you through the ups and downs of biotech development, helping you secure future rounds and scale your business effectively. 

Ready to accelerate your capital raise with expert strategic guidance?  

From CFO leadership and financial planning to investor targeting and outreach, Danforth Health is here to help you secure the funding your biotech company deserves. Connect with our experts today. 

In supporting 1,500+ biotech companies, we’ve seen it all.  

And we understand that in the early stages, it’s common to approach a biotech compensation strategy informally. Leaders are often quick to rely on peer anecdotes, venture capitalist guidance, or one-off negotiations. 

However, we’ve also seen that as biotech startups grow, this lack of compensation strategy structure soon becomes a problem, leading to overspending, internal misalignment, and worst of all, losing top talent. 

A thoughtful biotech compensation strategy from Day 1 sets your team up for success, bringing clarity and fairness to your pay practices while aligning with your mission, culture, and financial realities.  

Building a Biotech Compensation Strategy Step 1: Define Your Compensation Philosophy 

Your compensation philosophy is your north star, a formal document that outlines your company’s stance on: 

• Base pay 
• Bonuses 
• Cash vs. equity mix 
• Promotions and raises 
• Non-monetary perks 
• Remote or flexible work policy 

For example, your philosophy may define that your company targets the 50th percentile for both cash and equity compensation within your industry. It should reflect your values and financial strategy, as well as any legal requirements, and typically requires input from your CEO, CPO, and CFO, with final approval from the board. 

Building a Biotech Compensation Strategy Step 2: Create a Compensation Matrix 

A compensation matrix operationalizes your philosophy. It includes:

• Job descriptions & postings
• Job families, levels, and career ladders
• Benchmark salary data
• Clear pay bands
• Promotion pathways

This framework moves you away from ad hoc decision-making and toward standardized, scalable compensation practices. 

 Pro Tip: Use reputable benchmarking data to establish realistic, competitive salary bands. 

Building a Biotech Compensation Strategy Step 3: Plan Your Team and Address Outliers 

Once your matrix is in place, analyze where your current employees fall within it. Compare salaries against experience, skills, title, and performance. You may uncover: 

• Overpaid outliers with little rationale 
• Underpaid high performers who risk attrition 

 Address these gaps with a gradual, transparent adjustment plan. 

Building a Biotech Compensation Strategy Step 4: Tailor Your Benefits 

Compensation isn’t just about salary. Non-monetary benefits play a big role in employee satisfaction. Start by reviewing: 

• Demographics: Are employees early-career PhDs with student debt? Consider a qualified loan forgiveness program or a formal professional development budget. 
• Industry trends: In 2025, mental health support is increasingly expected. 
• Direct feedback: Surveys and focus groups can reveal what truly matters to your team. 

Building a Biotech Compensation Strategy Step 5: Communicate with Clarity 

Even the best compensation strategy fails if it isn’t clearly communicated. Ensure every employee understands: 

• Your compensation philosophy
• How salaries and raises are determined
• What they can do to grow their earnings

Use simple language, multiple channels, and involve managers and leadership in training. Transparency builds trust and reduces confusion or dissatisfaction. 

Set the Foundation Now for Long-Term Success 

Creating a compensation strategy for your biotech company might feel daunting, but it pays off in retention, performance, and compliance with evolving pay transparency laws. 

A strong compensation philosophy, combined with a practical matrix and clear communication, gives your biotech company the structure it needs to grow with confidence and attract the talent that will power your mission. 

Need help developing your compensation strategy? 

Danforth Health offers strategic HR guidance for biotech companies throughout all stages of their journey. Reach out to our expert team today. 

Clinical trial financial accruals often seem like a mystery to those outside of finance. But understanding how these accruals work is critical for clinical professionals who manage study operations and budgets. Whether you’re communicating with finance teams or overseeing vendor activities, learning the fundamentals of clinical trial financial accruals will help you run more efficient, compliant trials. 

What are Financial Accruals? 

In simple terms, financial accruals refer to the accounting practice of recognizing expenses when they are incurred, not when the cash is actually paid out. In a clinical trial context, this means tracking the services and activities that have occurred in a given month (e.g., patient visits, lab tests, CRO activity) and estimating their cost, even if the vendor hasn’t sent an invoice yet. 

These estimates are critical for proper monthly and quarterly financial reporting, especially in organizations that follow Generally Accepted Accounting Principles (GAAP). For example, if an investigator site completes five patient visits in April, the cost of those visits must be accrued in April, even if the invoice comes in May. 

Why Accruals Matter in Clinical Trials 

Accurate Financial Reporting: Investors, executives, and auditors expect financial statements to reflect the company’s current liabilities. Underestimating or overestimating trial costs can result in misleading reports, which can affect business decisions and even stock performance. 

Improved Budget Management: Trial costs are often spread out over months or even years. Accruals allow sponsors to track spending against the budget more precisely, flagging overages or cost-saving opportunities early on. 

Regulatory and Audit Readiness: Accurate and well-documented accruals help ensure transparency and readiness for internal audits or regulatory inspections. They also show that the organization maintains a disciplined approach to financial management. 

Common Challenges in Accrual Estimation 

Fragmented Data: Costs are often spread across multiple vendors, CROs, labs, imaging services, and investigator sites, making it difficult to get a full picture without robust tracking systems. 

Communication Gaps: Clinical teams may not always understand the level of detail finance teams need, leading to late or inaccurate reporting. Likewise, finance professionals may lack insight into clinical timelines and workflows. 

Inconsistent Methodologies: Some companies estimate based on invoices, while others use actual service logs or site forecasts. Without standardization, results can vary significantly from month to month.  

Best Practices for Clinical Teams 

Build Cross-Functional Communication: Set up recurring check-ins between clinical operations and finance during study start-up and ongoing execution. This helps both sides align on expectations, timelines, and deliverables. 

Maintain Clean and Consistent Data: Ensure that all vendor contracts clearly define cost-per-activity and invoicing terms. Use centralized systems to track patient activity and vendor performance in real time. 

Invest in Training and Tools: Educate clinical project managers on the basics of accruals. Equip them with templates or software that help simplify the tracking and forecasting process. 

Need expert support to manage your accruals? 

When clinical teams understand how clinical trial financial accruals work, they become better partners to finance teams, reduce budget errors, and strengthen the operational backbone of research. Having supported 1,500+ organizations, Danforth Health specializes in financial operations for life science companies. From accrual tracking to vendor forecasting, our experts can help you streamline your process and improve accuracy. Contact us today. 

Some of the most exciting life science breakthroughs are not coming from industry giants, but from small, scrappy biopharma companies operating with limited headcount, lean budgets, and sky-high expectations. These emerging players are proving that success in clinical development doesn’t require scale; it requires focus, strategy, and the right partnerships. 

But how do you execute high-stakes clinical trials with a lean team? 

The answer lies not in doing more, but in doing what matters most, exceptionally well. 

Lean Doesn’t Mean Weak 

There’s a persistent misconception in biotech that lean teams are at a disadvantage. But in reality, a streamlined approach often creates more agility, speed, and cohesion. The key is resisting the urge to overbuild, whether that’s staffing, systems, or SOPs, and instead building intentionally for the stage you’re at. 

For small biopharma companies, every dollar and decision must serve a purpose. Clinical operations should be a strategic extension of that mindset: designed to de-risk, drive value, and hit milestones without unnecessary layers or complexity. 

Strategy First, Not Systems First 

Having partnered with 1,500+ life science companies, we know that it’s tempting to start building infrastructure right away: filling roles, buying software, writing policies. But those steps are only useful when they’re anchored in a clear clinical strategy. 

Small teams benefit most from fit-for-purpose trial design: protocols shaped to hit regulatory goals, unlock new funding, or generate decision-making data. That often means working with experienced regulatory consultants early, prioritizing adaptive trial designs, and focusing narrowly on endpoints that matter. 

The result? You reduce the risk of costly rework, gain investor confidence, and build real momentum. 

Owning the Plan, Outsourcing the Execution 

With limited internal bandwidth, outsourcing is a given. But that doesn’t mean handing off control. Lean clinical teams should remain the strategic hub of every trial, while CROs, functional service providers, and consultants handle execution. 

What separates successful companies from the rest isn’t just who they outsource to, but how they manage those relationships. 

Smart vendor oversight is about structure, not scale: clear roles, shared KPIs, and consistent check-ins. One skilled clinical lead, armed with the right governance model, can keep multiple vendors aligned and accountable. 

Quality Without Bureaucracy 

Compliance is non-negotiable. But building a regulatory and quality function from scratch can feel overwhelming for a small company. The good news: it doesn’t have to be. 

Start with the essentials, documentation that supports Good Clinical Practice, and build outward. Lean companies often benefit from fractional QA consultants and cloud-based tools that provide structure without bureaucracy. It’s not about having a 100-page SOP library; it’s about having the right 10 pages in place. 

Partners Who Extend, Not Drain, Your Team 

One of the most overlooked drivers of operational success? Picking partners who behave like an extension of your team. 

Not every CRO or vendor is built for the scrappy, fast-moving world of early-stage biopharma. Bigger isn’t always better. The right partner will align with your culture, communicate transparently, and bring flexible staffing models that scale with you. They’ll move fast, solve problems, and stay focused on your goals, not just their deliverables. 

A great partner doesn’t just lighten the load; they elevate your execution. 

Small Teams, Big Advantage 

At the end of the day, your size can be your superpower. 

Lean biopharma companies are often more responsive, easier to work with, and more focused than their larger counterparts. Clinical sites and vendors appreciate sponsors who are accessible and decisive. Patients benefit from faster trial activation and more personalized recruitment strategies. 

When you stay lean and build intentionally, with the right strategy, tools, and people, you can run clinical operations that rival companies twice your size. It’s not about doing everything. It’s about doing the right things really well. 

Want to learn more about lean clinical operations?

Contact us to learn how our teammates at Elite BioPharma Consulting, a Danforth Health company, support small companies in scaling smartly and executing with excellence. 

Background

A private, clinical stage gene therapy company engaged Danforth Health’s Clinical Business Operations team to examine and resolve challenges related to the expenses of five clinical studies being managed by one Clinical Research Organization (CRO).

Danforth Health’s Role

Applying specialized expertise in clinical contracting, including clinical study accruals and related forecasting, the team identified multiple areas to avoid both over-payments and under-accruals. Findings included the following:

• Out-of-scope activities were being performed and were omitted from monthly accrual and forecasting reports. The Danforth team requested accrual data for all activities, including bookkept change notices, avoiding under-accrual of $900,000.
• Inflation cost of $2 million across trials was not included in the Statement of Work, budgets or month-end accrual reports. The Danforth team investigated the impact of inflation on study budgets to avoid under-accrual of $400,000.
• No detail was being provided for investigator grants. The Danforth team performed an audit of investigator grant payments, ultimately uncovering $200,000 in potential over-payments. Specifically, the audit revealed the following:
  • Lack of internal controls for duplicate visits (same subject and date); estimated overpayment of $52,000.
  • Internal control/process to update (reverse/pay) not functioning; estimated overpayment of $3700.
  • Payments made to sites for invoices lacking proper detail or supporting information (for example, a $57,000 hospital stay).
  • Payments made to sites for invoices that appear to be for same service/same time period or duplicate items on same invoice; estimated overpayment of $25,000.
  • Invoices pending approval and periodic site fees excluded from accrual file, resulting in under-accrual.
  • Numerous visits in Electronic Data Capture (EDC) had not been paid due to insufficient data and lack of CRO follow-up to ensure complete and accurate data entry from the sites.
  • Internal controls and processes not working as described, including visits deleted from EDC after payment without a credit being issued to site for “deleted” visits; estimated over-payment of $4700.
  • Payments to sites for visits and site costs in two different file layouts, lacking fields to cross-check and flag duplicates; estimated overpayment of $3700.

Based on these returns, the client has implemented Danforth’s custom-designed clinical finance tool as a long-term remedy to better predict clinical study spend and forecasting going forward.

Results

Implementing improved practices has led to a better understanding of the client’s clinical study liabilities/accruals and payments with more predictable forecasting. This methodology can also lead to improved relationships with CROs and sites by identifying trends and mitigating conflicts. 

Seeking help with clinical finance management?

Schedule a conversation with one of our experts.

For early-stage life science companies, selecting the right Contract Research Organization (CRO) is one of the most critical decisions in clinical development. At Danforth Health, having supported over 1,500 life science companies, we’ve found that what’s often overlooked is not who you choose, but how you structure the CRO contract. This foundational step can make or break the success of your clinical partnership. Implementing CRO contract best practices can help safeguard your investment, enforce accountability, and improve study outcomes. 

CRO Contract Best Practices Tip #1: Build Expectations Into the RFP 

One of the most overlooked CRO contract best practices is integrating key terms and expectations into the Request for Proposal (RFP), not just the final contract. By requiring CROs to respond to your proposed terms in the RFP stage, you filter out vendors unwilling or unable to meet your standards, giving you leverage before negotiations begin. 

CRO Contract Best Practices Tip #2: Document the Selection Process for FDA Readiness 

If your study comes under FDA review, you’ll need to justify your CRO selection. A best practice is to document your selection criteria, questions posed during the RFP process, and the responses received. This supports audit-readiness and demonstrates a thorough vetting process. 

CRO Contract Best Practices Tip #3: Tie Payments to Performance with Milestone-Based Models 

A key CRO contract best practice is to move away from time-based billing in favor of milestone-based payments. This aligns incentives with outcomes and helps ensure that deliverables, not delays, determine compensation. You can even include “earn-back” clauses to reward high-performing CROs with full contract value if they exceed expectations. 

CRO Contract Best Practices Tip #4: Include Consequences for Missed KPIs 

Defining Key Performance Indicators (KPIs) in your contract is only half the battle. A top CRO contracting best practice is to tie those KPIs to consequences, refunds, penalty clauses, or renegotiation triggers, so that performance has real weight. This sets clear expectations and helps both sides stay accountable. 

CRO Contract Best Practices Tip #5: Protect Yourself with Sponsor-Only Termination Rights 

Your contract should include termination for convenience, but that right should rest solely with the sponsor. Allowing the CRO to unilaterally terminate could jeopardize your clinical program. Fair terms for non-payment termination are reasonable, but they should include buffers, such as requiring two consecutive late payments before termination is permitted. 

CRO Contract Best Practices Tip #6: Define and Control Change Order Authorization 

One final best practice: don’t let change requests become liabilities. Specify who within your organization is authorized to approve change orders, and make clear that only approved, signed change orders, not informal requests, can result in billing. This avoids scope creep and financial surprises. 

A well-structured CRO contract isn’t just a safety net; it’s a strategic framework for clinical success. Embedding CRO contract best practices throughout the selection and negotiation process helps ensure alignment, reduce risk, and maximize outcomes. 

At Danforth Health, we support life science companies in building smart, performance-driven contracts that protect their investment and accelerate clinical execution. Need help designing your CRO strategy? Contact our team today. 

Clinical trial financial accruals require close coordination between clinical operations and finance departments. Unfortunately, many organizations suffer from misaligned processes, unclear roles, and inconsistent reporting.  

Why the Disconnect Around Clinical Trial Financial Accruals Exists 

Clinical and finance teams often work with different goals in mind. Clinical staff prioritize patient recruitment, site performance, and trial timelines. Finance teams, on the other hand, are focused on budget accuracy, cash flow, and monthly close deadlines. 

This misalignment creates situations where: 

• Clinical teams don’t report activities on time, leading to under-accrual. 
• Finance teams request cost estimates without understanding how studies are operationalized. 
• No one takes ownership of reconciling trial progress with financial reports. 

When both clinical and finance teams understand the goals of clinical trial financial accruals, collaboration becomes more effective. 

Consequences of Poor Collaboration 

Inaccurate Financial Reporting: Without timely and accurate input from clinical teams, finance departments may guess or delay their accruals, affecting external audits or investor confidence. 

Budget Overruns: Lack of transparency can cause clinical programs to exceed budgets before leadership realizes there’s a problem. 

Operational Bottlenecks: Time wasted on chasing down data or correcting accrual errors takes valuable attention away from study execution. 

Strategies to Strengthen Cross-Functional Collaboration 

Establish Shared Language and Goals: Develop a basic financial literacy program for clinical teams and help finance staff understand how trials progress. Align on key metrics that matter to both sides, such as cost-per-visit or site activation timelines. 

Hold Regular Joint Planning Sessions: Don’t wait until a problem arises. Schedule recurring meetings where clinical and finance leads review trial milestones, spending to date, and accrual estimates. 

Use Integrated Systems and Tools: Centralized clinical trial management systems (CTMS) that feed into finance systems can reduce manual reporting errors and create a single source of truth. 

Define Roles and Responsibilities: Clearly outline who is responsible for reporting site activity, updating vendor timelines, and submitting forecasts. Remove the guesswork from collaboration. 

Document Accrual Assumptions: Create audit trails and documentation for how accruals were estimated. This provides transparency and allows for better review in future months or trials. 

The Result? 

Proactive collaboration around clinical trial financial accruals leads to more accurate budgets, greater cross-functional trust, and improved trial efficiency. Looking to bridge the gap between clinical and finance teams? Danforth Health provides fractional finance support tailored to biotech and life science companies. We help teams align around accruals, budgeting, and forecasting for greater operational efficiency. Contact us today. 

Maintaining respectful, open dialogue at work has become more important and challenging than ever. The rise of social and political discourse spilling into work environments has left many leaders scrambling to manage civil discourse in the workplace, leaving them to wonder: How do we protect culture without stifling individuality? 

Managing civil discourse in the workplace starts with a proactive plan rooted in your company’s values. 

“When people don’t know the boundaries, it’s hard to enforce them. You have to be clear, not just in your policies, but in how you live them out day to day.” 

This statement, shared during our recent conversation with an expert Danforth Health HR consultant, captures the essence of managing workplace conflict. Your company culture is defined by how you approach disagreement, not just how you celebrate success. 

#1: Revisit Your Mission and Values 

When a workplace conflict arises, leadership must ask: Is this about behavior, or is it a deeper value misalignment? Reaffirming your mission and values can help guide that assessment. Make sure your team knows: 

1. What the company stands for 
2. What behaviors are encouraged 
3. What the non-negotiables are 

#2: Understand the Legal Landscape

There’s a common misconception that “free speech” protections automatically extend into the private workplace. In reality, free speech does not apply the same way within private organizations. Employers have the right to and the legal obligation to set boundaries, especially when speech veers into harassment, disruption, or discrimination. 

To manage civil discourse in the workplace, know what is and isn’t protected and train your managers accordingly. If your managers feel unsure about what they can address, they’ll often say nothing, and that silence can do real damage.

#3: Don’t Wait for the Fire- Build the Extinguisher Now 

Only 8% of organizations have a formal policy around civil discourse in the workplace. That’s a missed opportunity. A well-crafted civil discourse policy can: 

• Clarify behavioral expectations 
• Provide a roadmap for conflict resolution  
• Reinforce cultural norms 

Your action plan should include:

• A clearly communicated code of conduct  
• Manager training on conflict resolution and inclusive dialogue 
• A protocol for escalating and resolving issues 
• Being fully compliant with various sections of the National Labor Relations Act  

Is your organization prepared? Don’t wait for conflict or a legal issue to force your hand when it comes to managing civil discourse in the workplace. The time to define expectations and protect your culture is now. Danforth Health can help you build a proactive policy and response plan tailored to your organization. Contact us today. 

Too often, companies delay commercial strategy until late-stage development, assuming it’s a downstream task. However, the vast majority, 80–90% of drugs in development, must prioritize biotech commercial planning much earlier than they think. Delaying commercial readiness can create compounding risks that threaten your funding, your timeline, and your launch success. 

Here’s what’s at stake when biotech commercial planning gets pushed too far down the road. 

1. Reduced Investor or Acquirer Interest 

Investors and acquirers today expect a robust early commercial strategy to accompany your clinical plan. Without a compelling commercial narrative, you risk being overlooked in favor of competitors who can clearly demonstrate product-market fit and growth potential. 

Biotech companies that delay commercial planning often struggle to: 

• Secure critical funding. 
• Attract interest from potential acquirers or partners. 
• Build credibility with key stakeholders. 

Biotech commercial planning isn’t a nice-to-have; it’s a prerequisite for investor confidence. 

 2. Misalignment with Market, Patients, and Payers 

If you wait too long to engage commercial functions, your development path may overlook critical market factors: 

• Is your product differentiated enough? 
• Will payers reimburse it? 
• Are you solving a true unmet need? 

Without early insights from market research and payer engagement, you risk launching a product that doesn’t resonate, or worse, one that doesn’t get covered. 

 3. Launch Delays 

A delayed start to commercial planning in biotech often creates major gaps: 

• Incomplete market understanding. 
• Lack of secondary data to support claims. 
• Underdeveloped KOL or HCP engagement plans. 

These gaps can delay your biotech product launch by months or even years, ultimately reducing the product’s lifetime value and competitive edge. 

 4. Costly Last-Minute Changes 

When commercial needs come into focus late, the resulting pivots are often expensive: 

• Retrofitting clinical trials. 
• Rushing to collect new data. 
• Overhauling messaging or branding at the eleventh hour. 

All of these emergency efforts drive up costs and reduce launch efficiency. By contrast, early biotech commercial planning allows you to integrate commercial considerations from the outset: saving time, money, and resources. 

 5. Underperformance at Launch 

Studies show that only 20–30% of first-time launchers meet or exceed commercial expectations. Why? It’s rarely the science. More often, it’s the absence of a well-structured, realistic commercial plan. 

Companies that invest in commercial readiness early are far better equipped to: 

• Navigate payer negotiations. 
• Educate physicians and patients. 
• Build internal capabilities that support long-term growth. 

The Takeaway: Plan Early, Win Bigger 

If you’re not developing a first-in-class or ultra-orphan drug, the market won’t give you much breathing room. For most companies, biotech commercial planning should begin in Phase 2 or earlier, not post-approval. 

By prioritizing early market insight, stakeholder alignment, and strategic planning, your team can reduce risk and maximize the return on years of clinical effort. 

Need guidance on when and how to start your biotech commercial planning? 

Our team specializes in helping biopharma teams build commercial strategies that scale with development. Connect with us today. 

Insights From an Expert: Written by Chris Mycek, Head of Commercialization, BW Health Group, A Danforth Health Company

Applying Nature’s Growth Patterns to Life Sciences Commercialization

As we help clients navigate the complex world of life sciences commercialization strategy from clinical promise to commercial success, I’m struck by how often sustainable growth follows patterns found in nature. The Fibonacci sequence—where each number is the sum of the two preceding ones (1, 1, 2, 3, 5, 8, 13, 21…)—offers a compelling framework for thinking about organizational development in life sciences commercialization. What we’re looking to achieve is healthy, sustainable growth…so why not look to Mother Nature for an answer?

The Seed Stage: 1, 1

Every successful life sciences commercialization strategy begins with two fundamental elements that must be equally strong: a differentiated clinical asset and a clear understanding of unmet patient need. Like the first two numbers in the Fibonacci sequence, these elements stand alone yet together form the foundation for everything that follows.

Too often, I see pre-commercial organizations fixate exclusively on clinical data while underinvesting in market research. Both must receive equal attention. Even groundbreaking science fails commercially when disconnected from provider and patient realities.

Early Growth: 2, 3, 5

As organizations advance toward commercialization, each new capability should build upon established strengths. The “2” represents the initial commercial leadership—typically the Chief Commercial Officer and Medical Affairs lead who synthesize clinical and market insights into a coherent strategy.

The “3” emerges as this core team expands to include market access expertise—critical for today’s value-based reimbursement environment. These three functions together shape the “5”—the essential commercial workstreams: brand strategy, pricing architecture, distribution model, field deployment planning, and launch sequencing.

This natural progression prevents the common pitfall I witness repeatedly: prematurely scaling commercial infrastructure before foundational elements are solidified. In a successful life sciences commercialization strategy, each new function should emerge from and be supported by previous capabilities.

Accelerating Momentum: 8, 13, 21

As launch approaches, organizations face tremendous pressure to rapidly expand. The Fibonacci pattern reminds us that growth should accelerate naturally but proportionally. The “8” in this life sciences commercialization strategy represents the expanded commercial roles—adding sales leadership, marketing specialists, and account management strategists who build upon the core team’s vision.

The “13” often reflects field deployment. Here, I counsel clients to resist arbitrary size targets. Instead, align field force scale precisely with the strategic focus established earlier. Organizations that skip steps in this progression invariably struggle with misalignment and excessive burn rates.

The “21” represents the full commercial organization post-launch, including support functions, analytics teams, and expanded medical capabilities. When built according to this natural progression, these teams work with remarkable synchronicity.

Sustainable Balance

Nature employs the Fibonacci sequence because it creates balanced, sustainable systems. Similarly, the most successful life sciences commercialization strategy follows this organic pattern rather than artificially accelerated timelines that create organizational stress fractures.

For pre-commercial organizations, particularly those launching their first asset, the temptation to simultaneously build all commercial capabilities is almost irresistible. The Fibonacci framework offers a disciplined alternative: methodical capability building where each new function reinforces rather than dilutes organizational focus.

Practical Application

When advising clients on life sciences commercialization strategy, we now explicitly map organizational development against this Fibonacci framework. This approach has helped several recent clients:

• A Phase II oncology company reallocated resources from premature sales infrastructure to deeper market research, ultimately sharpening their differentiation strategy
• A rare disease organization restructured their hiring sequence to strengthen core market access capabilities before expanding marketing functions
• A CNS-focused company redesigned their launch timeline to ensure adequate integration between medical affairs and commercial teams before field expansion

The most elegant solutions in nature and business share a common characteristic: simplicity that creates sustainable complexity. By following the natural growth pattern of the Fibonacci sequence, life sciences organizations can build commercial capabilities that reinforce rather than compete with each other.

In an industry where overbuilding and subsequent restructuring have become distressingly common, this approach offers a path to more sustainable growth, with the potential to bring life-changing therapies to patients more efficiently and effectively.

Successful commercialization in life sciences doesn’t happen by chance; it requires the right team, the right timing, and the right strategy. That’s where we come in. Build your commercialization strategy the smart, scalable way. Contact our team today.